Medication Exposures and Subsequent Development of Ewing Sarcoma: A Review of FDA Adverse Event Reports
Table 1
Summary of FAERS reports of medication use prior to Ewing Sarcoma Family of Tumor (ESFT) diagnosis, 1997–2013. Total = 25; 13 US, 12 foreign; 16 females, 9 males. Ages 4–68 years (median age 24 years; mean 30 years). Known latency for 20 patients: 3 months–12 years (median 27 months; mean 3.2 years); 5 unknown.
(a)
Report year
Number of cases
1997–1999
1
2000–2004
6
2005–2009
9
2010–2013
9
(b)
Drug use
Number of cases
Patient age (yrs)
Latency
Immunosuppressive
12
5–68
Mean 4.2 years, median 4 years
Growth hormone (GH)
2
11, 16
4 months after 5 years therapy, 18 months
Estrogen/progestin
2
24, 47
10 months, 2.5 years
CNS depressant
2
34, 42
22 months, unknown
Atypical antipsychotic
1
17
No information
Antiepileptic
1
8
8 years
Antipsychotic and AED
1
19
3 months
ADHD
1
8
No information
Isotretinoin
1
20
10 months
Statin for hyperlipidemia
1
9
>2 years
rPTH
1
49
1 year
1 Crohn’s patient also received GH. rPTH, recombinant parathyroid hormone.
